In his newest column, Sarfaraz K. Niazi, PhD, looks into the domestic and international support for removing interchangeability for biosimilars in the United States.
Only the United States has 2 classes of biosimilars, one that has no clinically meaningful difference with the reference product and the other interchangeable biosimilar that undergo additional extensive testing. Both are tested the same way yet get awarded different statuses, a practice that has greatly damaged the adoption of biosimilars in the US.[1] (Figure 1).
Removing interchangeability is supported by several arguments:[2]
To remove the interchangeability status, Senator Lee has introduced a bill in the Senate that modifies the language in the BPCIA. The passage of this bill will bring the FDA in concordance with the rest of the regulatory agencies, remove misconceptions about biosimilars and expedite the adoption of biosimilars. In addition, biosimilars can also be switched with other biosimilars, and both the European Medicines Agency[4] and the United Kingdom’s Medicines and Healthcare products Regulatory Agency[5] have issued specific clarifications removing all interchangeable designations. No other global regulatory agency offers interchangeability; it is treated like any other drug, where the prescriber decides whether to substitute.
I invite my colleagues and stakeholders to write to me to add to or question the conclusions drawn in this article at niazi@niazi.com.
References
[1] Biosimilar info sheet. FDA. Accessed December 13, 2022. https://www.fda.gov/media/154917/download
[2] Niazi SK. No two classes of biosimilars: urgent advice to the US Congress and the FDA. J Clin Pharm Ther. 2022;47(9):1352-1361. doi:10.1111/jcpt.13743
[3] Biosimilar product information. FDA. Updated December 7, 2022. Accessed December 13, 2022. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
[4] Biosimilar medicines can be interchanged. EMA. September 19, 2022. Accessed December 13, 2022. https://www.ema.europa.eu/en/news/biosimilar-medicines-can-be-interchanged
[5] Guidance on the licensing of biosimilar products. United Kingdom’s MHRA. November 7, 2022. Accessed December 13, 2022. https://www.gov.uk/government/publications/guidance-on-the-licensing-of-biosimilar-products/guidance-on-the-licensing-of-biosimilar-products
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.